To include your compound in the COVID-19 Resource Center, submit it here.

Infergen interferon alfacon-1: Marketed

In a study of 554 patients with chronic HCV who had relapsed or had not responded

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE